Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient demographics and baseline characteristics

From: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT

CharacteristicPBO, n = 221UPA 15 mg, n = 221UPA 30 mg, n = 219
Age (years), mean ± SD56.0 ± 12.255.3 ± 11.555.8 ± 11.3
Female, n (%)166 (75.1)182 (82.4)172 (78.5)
White, n (%)187 (84.6)188 (85.1)186 (84.9)
Duration RA diagnosis (years), mean ± SD7.2 ± 7.57.3 ± 7.97.3 ± 7.9
Duration of RA (≥ 5 years), n (%)99 (44.8)98 (44.3)102 (46.6)
CDAI, mean ± SD37.8 ± 11.838.3 ± 11.938.6 ± 12.7
DAS28-CRP, mean ± SD5.6 ± 0.85.7 ± 1.05.7 ± 0.9
Seropositive for RF, n (%)164 (74.2)163 (73.8)146 (66.7)
Anti-CCP antibody positive, n (%)167 (75.9)174 (79.1)155 (70.8)
Tender joint count (of 68), mean ± SD24.7 ± 15.025.2 ± 13.826.2 ± 14.3
Swollen joint count (of 66), mean ± SD15.4 ± 9.216.0 ± 10.016.2 ± 10.6
csDMARD use at baseline, n (%)
 MTX alone141 (64.1)122 (55.5)136 (62.1)
 MTX plus other csDMARD49 (22.3)47 (21.4)39 (17.9)
 csDMARD other than MTX30 (13.6)51 (23.2)44 (20.1)
 Missing1 (< 1)1 (< 1)0
  1. CCP cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, CRP C-reactive protein, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28-CRP Disease Activity Score 28 using C-reactive protein, MTX methotrexate, PBO placebo, RA rheumatoid arthritis, RF rheumatoid factor, SD standard deviation, UPA upadacitinib